If you have been reading about anti-doping and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
In drug development and production, good clinical practice (GCP) is an international quality standard, which governments can then transpose into regulations for clinical trials involving human subjects. GCP follows the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), and enforces tight guidelines on ethical aspects of clinical research. High standards are required in terms of comprehensive documentation for the clinical protocol, record keeping, training, and facilities, including computers and software. Quality assurance and inspections ensure that these standards are achieved. GCP aims to ensure that the studies are scientifically authentic and that the clinical properties of the investigational product are properly documented. GCP guidelines include protection of human rights for the subjects and volunteers in a clinical trial. It also provides assurance of the safety and efficacy of the newly developed compounds. GCP guidelines include standards on how clinical trials should be conducted, define the roles and responsibilities of institutional review boards, clinical research investigators, clinical trial sponsors, and monitors. In the pharmaceutical industry monitors are often called clinical research associates. A series of unsuccessful and ineffective clinical trials in the past were the main reason for the creation of ICH and GCP guidelines in the US and Europe.
=== Metabolism: 20th century – present === One of the most prolific of these modern biochemists was Hans Krebs who made huge contributions to the study of metabolism. Krebs was a student of extremely important Otto Warburg, and wrote a biography of Warburg by that title in which he presents Warburg as being educated to do for biological chemistry what Fischer did for organic chemistry. Which he did. Krebs discovered the urea cycle and later, working with Hans Kornberg, the citric acid cycle and the glyoxylate cycle. These discoveries led to Krebs being awarded the Nobel Prize in physiology in 1953, which was shared with the German biochemist Fritz Albert Lipmann who also codiscovered the essential cofactor coenzyme A.
=== Glioma and chemotherapy resistance === ITGA1 has been implicated in resistance to glioma treatment as well. The particular treatment it is resistant to is temozolomide (TMZ), which is the standard first-line chemotherapy agent used with radiotherapy and adjuvant treatment. There is an observed elevation of ITGA1 expression in TMZ-resistant glioma tissues when compared with a control group of TMZ-sensitive cell lines. Tumor cell survival is promoted by ITGA1 activating the PI3K/AKT pathway, subsequently increasing the anti-apoptotic Bcl-2 signaling and reducing apoptosis. A regulatory pathway involving hsa_circ_0110757 and hsa-miR-1298-5p controls ITGA1 expression in TMZ-resistant glioma. hsc_circ_0110757 functions as a competing endogenous RNA by sponging miR-1298-5p, which promotes ITGA1 expression and leads to increased PI3K/AKT activation as well as reduced apoptosis, and enhanced TMZ resistance. Disrupting this pathway restores the cell sensitivity to chemotherapy. This supports ITGA1 as a possible therapeutic target to overcome drug resistance in glioma.
Sources: en.wikipedia.org
Generative AI models are used by chatbots such as ChatGPT, programming tools such as GitHub Copilot, text-to-image programs such as Midjourney, and text-to-video programs such as Runway Gen-2. Generative AI features have been added to existing commercially available services such as Microsoft Office (Microsoft Copilot), Google Photos, and the Adobe Suite (Adobe Firefly). Many generative AI models are also available as open-source software, including Stable Diffusion and the LLaMA language model. Smaller generative AI models with up to a few billion parameters can run on smartphones, embedded devices, and personal computers. For example, LLaMA-7B (a version with 7 billion parameters) can run on a Raspberry Pi 4 and one version of Stable Diffusion can run on an iPhone 11. Larger models with tens of billions of parameters can run on laptop or desktop computers. To achieve an acceptable speed, models of this size may require accelerators such as the GPU chips produced by NVIDIA and AMD or the Neural Engine included in Apple silicon products. For example, the 65 billion parameter version of LLaMA can be configured to run on a desktop PC. The advantages of running generative AI locally include protection of privacy and intellectual property, and avoidance of rate limiting and censorship. The subreddit r/LocalLLaMA in particular focuses on using consumer-grade gaming graphics cards through such techniques as compression.
Patients with active internal bleeding Patients with a recent (within 3 months) hemorrhagic stroke Patients with a recent (within 2 months) intracranial/intraspinal surgery/severe head trauma Trauma patients with an increased risk of life-threatening bleeding Patients with an epidural catheter Patients with a known or suspected intracranial neoplasm or mass lesion Patients with known hypersensitivity to drotrecogin or any component
==== Termination of Peter Rost (2005) ==== Peter Rost was vice president in charge of the endocrinology division at Pharmacia before its acquisition by Pfizer. During that time he raised concerns internally about kickbacks and off-label marketing of Genotropin, Pharmacia's human growth hormone drug. Pfizer reported the Pharmacia marketing practices to the FDA and Department of Justice; Rost was unaware of this and filed an FCA lawsuit against Pfizer. Pfizer kept him employed, but isolated him until the FCA suit was unsealed in 2005. The Justice Department declined to intervene, and Pfizer fired him, and he filed a wrongful termination suit against Pfizer. Pfizer won a summary dismissal of the case, with the court ruling that the evidence showed Pfizer had decided to fire Rost prior to learning of his whistleblower activities.
==== Gliomas ==== A glioma is essentially a glial-derived tumor. These can be induced by an increase in glutamate levels due to an increase in system Xc- activity. Using inhibitors of system Xc- as a treatment for gliomas is currently under active investigation.
Sources: en.wikipedia.org
Electron transfers Electron transfer (ET) between metal ions can occur via two distinct mechanisms, inner and outer sphere electron transfers. In an inner sphere reaction, a bridging ligand serves as a conduit for ET. (Degenerate) ligand exchange One important indicator of reactivity is the rate of degenerate exchange of ligands. For example, the rate of interchange of coordinate water in [M(H2O)6]n+ complexes varies over 20 orders of magnitude. Complexes where the ligands are released and rebound rapidly are classified as labile. Such labile complexes can be quite stable thermodynamically. Typical labile metal complexes either have low-charge (Na+), electrons in d-orbitals that are antibonding with respect to the ligands (Zn2+), or lack covalency (Ln3+, where Ln is any lanthanide). The lability of a metal complex also depends on the high-spin vs. low-spin configurations when such is possible. Thus, high-spin Fe(II) and Co(III) form labile complexes, whereas low-spin analogues are inert. Cr(III) can exist only in the low-spin state (quartet), which is inert because of its high formal oxidation state, absence of electrons in orbitals that are M–L antibonding, plus some "ligand field stabilization" associated with the d3 configuration. Associative processes Complexes that have unfilled or half-filled orbitals are often capable of reacting with substrates. Most substrates have a singlet ground-state; that is, they have lone electron pairs (e.g., water, amines, ethers), so these substrates need an empty orbital to be able to react with a metal centre.
== Applications == Enzyme inhibitors are found in nature and also produced artificially in the laboratory. Naturally occurring enzyme inhibitors regulate many metabolic processes and are essential for life. In addition, naturally produced poisons are often enzyme inhibitors that have evolved for use as toxic agents against predators, prey, and competing organisms. These natural toxins include some of the most poisonous substances known. Artificial inhibitors are often used as drugs, but can also be insecticides such as malathion, herbicides such as glyphosate, or disinfectants such as triclosan. Other artificial enzyme inhibitors block acetylcholinesterase, an enzyme which breaks down acetylcholine, and are used as nerve agents in chemical warfare.
Naram-Sin, also transcribed Narām-Sîn or Naram-Suen (Akkadian: 𒀭𒈾𒊏𒄠𒀭𒂗𒍪: DNa-ra-am DSîn, meaning "Beloved of the Moon God Sîn", the "𒀭" a determinative marking the name of a god; died c. 2218 BC), was a ruler of the Akkad, who reigned c. 2255–2218 BC (middle chronology), and was the third successor and grandson of King Sargon of Akkad. Under Naram-Sin, the kingdom reached its maximum extent. He was the first Mesopotamian king known to have claimed divinity for himself, taking the title "God of Akkad", and the first to claim the title "King of the Four Quarters". His military strength was strong as he crushed revolts and expanded the kingdom to places like Turkey and Iran. He became the patron city god of Akkade as Enlil was in Nippur. His enduring fame resulted in later rulers, Naram-Sin of Eshnunna and Naram-Sin of Assyria as well as Naram-Sin of Uruk, assuming the name.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.